
Antibody-drug conjugate company CrossBridge Bio acquired by Lilly
Eli Lilly has signed a definitive agreement to acquire preclinical biotechnology company CrossBridge Bio for up to $300 million in cash, inclusive of an upfront payment and a subsequent milestone-dependent payment. CrossBridge Bio, a Houston-based biotechnology firm founded in 2023, is developing a new dual-payload ADC technology originally created by… Read More
